Trial Profile
Phase Ib Study of Monoclonal Antibody to OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer After Systemic Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; MEDI 6469 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; Therapeutic Use
- 27 Aug 2018 Status changed from active, no longer recruiting to completed.
- 13 Jun 2017 Planned End Date changed from 1 Oct 2017 to 1 Oct 2020.
- 13 Jun 2017 Planned primary completion date changed from 1 Oct 2016 to 1 Oct 2018.